Topic:
Partnering
Latest Headlines
Latest Headlines
Amid cheers and jeers, GlaxoSmithKline reveals Duchenne drug hit PhII goal
After keeping its mid-stage data for a closely-watched and controversial drug for Duchenne muscular dystrophy under wraps, GlaxoSmithKline has pulled back part of the covers to reveal that drisapersen did in fact hit the primary endpoint on walking distance.
Ambrx's cancer antibody delivery tech wins Astellas partnership
San Diego-based Ambrx welcomed an influx of cash for the further development of its drug-delivery technology: antibody drug conjugates, or ADCs.
GlaxoSmithKline inks 5-year R&D pact with A*STAR
The two groups have been working together for the past decade, helping build the city-state's reputation for R&D.
Ex-FDA head: End barriers between devices, Dx and drugs
Device, diagnostics and drug companies should be working together and sharing intellectual property at a much sooner point in their research, argues Dr. Andrew von Eschenbach, who ran the FDA from 2005 to 2009.
Roche rolls out $392M Isis pact in two-pronged attack on Huntington's
Roche has stepped up with a $392 million deal designed to marry its work on new technology for delivering brain treatments with Isis' antisense programs for Huntington's disease. In the deal, the latest in a lengthy string for the Carlsbad, CA-based biotech company, Isis gains $30 million upfront with the rest payable on promised milestones.
BSD turns to Terumo in global ablation device distribution deal
BSD Medical inked a wide-ranging deal with Japanese med tech giant Terumo to distribute one of its signature tumor ablation devices in Europe, Western Asia and North Africa.
InVentiv sells sample management biz to Knipper
Global CRO InVentiv Health is shipping out its sample management business to J. Knipper and focusing instead on its other clinical and commercial offerings.
Some still skeptical of BRAIN initiative as details remain fuzzy
President Barack Obama's highly anticipated BRAIN initiative--short for Brain Research Through Advancing Innovative Neurotechnologies--has the lofty goal of mapping the human brain in hopes of finding new treatments for diseases like Alzheimer's, Parkinson's and other neurological disorders.
Astellas, Ambrx seal $300M cancer ADC deal
Astellas Pharma has wagered on antibody drug conjugate tech from the San Diego biotech startup Ambrx, paying $15 million upfront and committing up to $285 million more in their collaboration focused in oncology. And it's more proof that major pharma outfits are keen on the advantages of pairing targeted antibodies with potent drug payloads to treat cancer.
Celgene-backed Agios and Foundation partner in breakthrough cancer strategy
Agios has teamed up with Foundation Medicine to find patients with the genetic profiles most suited to treatment on Agios therapies concerning two cancer metabolism targets.
